- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06386003
Terapia di elaborazione cognitiva assistita da psilocibina per il disturbo da stress post-traumatico cronico
Terapia di elaborazione cognitiva massiva assistita da psilocibina per il disturbo da stress post-traumatico cronico: uno studio in aperto
This is an open-label trial evaluating feasibility, tolerability, safety and efficacy of psilocybin assisted cognitive processing therapy for chronic Posttraumatic Stress Disorder (PTSD).
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Current front-line treatments for Posttraumatic stress disorder (PTSD) are ineffective for up to half of patients, with serious medical and societal consequences. It is imperative to improve the efficacy of front-line treatment options, such as cognitive processing therapy (CPT). CPT is an effective treatment for PTSD, including when delivered intensively (i.e., multiple sessions over 7 days). However, a substantial proportion of patients continue to meet criteria for PTSD or have residual PTSD symptoms post-treatment. Psilocybin-assisted CPT may be a potential solution, as preliminary evidence supports the potential of psilocybin to alleviate symptoms of PTSD.
Fifteen participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days. Participants will complete clinician-administered scales, self-reported mental health questionnaires, and use a wearable device. After the 1-week interventional period, participants will enter a 12-weeks follow-up period.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Ontario
-
Toronto, Ontario, Canada, M5S 1A1
- St. Michael's Hospital, Unity Health Toronto
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Meet Diagnostic and Statistical Manual-5th edition (DSM-5) criteria for current PTSD with a duration of 6 months or longer assessed by study psychiatrist;
- Have a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score of 50 or higher, indicating moderate to severe PTSD symptoms;
- Are willing to refrain from taking any psychiatric medications during the study period.
Exclusion Criteria:
- Are pregnant or nursing, or are women of child bearing potential who are not practicing an effective means of birth control;
- Have a history of or a current primary diagnosis of psychotic disorder, schizophrenia, delusional disorder, borderline personality disorder, schizoaffective disorder, bipolar disorder or, dissociative identity disorder;
- Have evidence or history of coronary artery disease or cerebral or peripheral vascular disease, hepatic disease with abnormal liver enzymes, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration;
- Have hypertension using the standard criteria of the American Heart Association (values of 140/90 or higher assessed on three separate occasions;
- History of seizure disorder;
- Uncontrolled insulin-dependent diabetes;
- Recent stroke, intracranial or subarachnoid hemorrhage (< 1 year from signing of informed consent form [ICF]), recent myocardial infarction (< 1 year from signing of ICF), clinically significant arrhythmia (< 1 year from signing of ICF);
- Have liver disease with the exception of asymptomatic subjects with Hepatitis C who have previously undergone evaluation and successful treatment;
- Lifetime history of substance-induced psychosis;
- Lifetime history of substance use disorder with a hallucinogen;
- History of alcohol use disorder in the past 3 months.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Experimental
Single dose of psilocybin 25mg + Massed cognitive processing therapy |
Participants will receive a single dose of psilocybin 25mg combined with 12 sessions of massed CPT, and 2 psychotherapy sessions related to psilocybin over 7 days. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Feasibility and tolerability
Lasso di tempo: Up to 16 weeks
|
Recruitment rate, withdrawal rate, adherence rate, data completion rate, percentage of participants with severe adverse events. |
Up to 16 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Childhood Trauma Questionnaire-short form (CTQ-SF)
Lasso di tempo: Screening
|
Screening
|
|
|
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score
Lasso di tempo: Up to 16 weeks
|
The CAPS-5 is a semi-structured clinical interview used to assess index history of DSM-5-defined traumatic event exposure, including the most distressing event, time since exposure, and total number of exposures, as well as frequency and severity of posttraumatic stress symptoms. |
Up to 16 weeks
|
|
Posttraumatic stress disorder Checklist-5 (PCL-5)
Lasso di tempo: Up to 16 weeks
|
The PCL-5 is self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the DSM-5 symptoms of PTSD. |
Up to 16 weeks
|
|
Patient Health Questionnaire-9 (PHQ-9)
Lasso di tempo: Up to 16 weeks
|
The PHQ-9 is a self-rated measure of depressive symptom severity in the past two weeks. Each of the nine items is rated on a Likert scale, ranging from 0 (not at all) to 3 (nearly every day), and summed for a total score between 0 (no symptoms) to 27 (most severe). |
Up to 16 weeks
|
|
Generalized Anxiety Disorder Scale, 7-item (GAD-7)
Lasso di tempo: Up to 16 weeks
|
Total score ranges from 0 to 21; a higher score denotes greater symptom severity. |
Up to 16 weeks
|
|
Dissociative Experiences Scale II (DES-II)
Lasso di tempo: Up to 13 weeks
|
The Dissociative Experiences Scale II is a 28-item, self-report measure of dissociative experiences. |
Up to 13 weeks
|
|
Pittsburgh Sleep Quality Index (PSQI)
Lasso di tempo: Up to 13 weeks
|
The PSQI is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. |
Up to 13 weeks
|
|
World Health Organization Well-Being Index, 5-item (WHO-5)
Lasso di tempo: Up to 16 weeks
|
The WHO-5 is a measure of overall well-being, rated on a scale of 0 to 25, with higher scores denoting higher quality of life. |
Up to 16 weeks
|
|
Quality of relationships inventory (QRI)
Lasso di tempo: Up to 13 weeks
|
The QRI is a self-report questionnaire used to determine the quality relationships consisting of 25 items that are evaluated on a 4-point Likert scale ranging from 1 = not true to 4 = almost always true. |
Up to 13 weeks
|
|
Inventory of psychosocial functioning (IPF)
Lasso di tempo: Up to 13 weeks
|
The IPF is an 80-item self-report instrument measuring PTSD-related functional impairment in the past 30 days. |
Up to 13 weeks
|
|
Posttraumatic Maladaptive Beliefs Scale (PMBS)
Lasso di tempo: Up to 13 weeks
|
The PMBS is a 15-item scale that was developed to measure maladaptive beliefs about life circumstances that may occur following trauma exposure. |
Up to 13 weeks
|
|
Brief Experiential Avoidance Questionnaire (BEAQ)
Lasso di tempo: Up to 13 weeks
|
The BEAQ is a 15-item self-report measure of experiential avoidance. |
Up to 13 weeks
|
|
24-items Multidimensional Psychological Flexibility Inventory (MPFI-24)
Lasso di tempo: Up to 13 weeks
|
The MPFI-24 is a 24-item self-report scale developed to assess the specific components of psychological flexibility and inflexibility. |
Up to 13 weeks
|
|
Working Alliance Inventory- Short Form (WAI-SF)
Lasso di tempo: Up to Day 7
|
The WAI-SF is a patient-rated measure of the alliance between a therapist and client. |
Up to Day 7
|
|
Difficulties in Emotion Regulation Scale-Short Form (DERS-SF)
Lasso di tempo: Up to 13 weeks
|
The DERS-SF is an 18-item measure used to identify emotional regulation issues in adults. |
Up to 13 weeks
|
|
Self-Compassion Scale-Short Form (SCS-SF)
Lasso di tempo: Up to 13 weeks
|
The SCS-SF is a 12-item self-report measure of self-compassion. |
Up to 13 weeks
|
|
Psychological Insight Questionnaire (PIQ)
Lasso di tempo: Up to Day 3
|
The PIQ is a 23-item self-report measure of acute experiences of insight (e.g. awareness into emotions, behaviors, beliefs, memories, or relationships) after taking a psychedelic. |
Up to Day 3
|
|
Emotional Breakthrough Inventory (EBI)
Lasso di tempo: Up to Day 3
|
The EBI is a measure of emotional release/breakthrough experienced during the acute psychedelic state. |
Up to Day 3
|
|
Altered States of Consciousness Rating Scale (ASC)
Lasso di tempo: Up to Day 3
|
The ASC measures altered states of consciousness. |
Up to Day 3
|
|
Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ)
Lasso di tempo: Up to Day 3
|
The APEQ is a psychometric self-report tool for measuring aspects of the acute psychedelic experience that are associated with longer-term changes in psychological flexibility. |
Up to Day 3
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Effect on digital physiological passive data collected through the use of a wearable device
Lasso di tempo: Up to 16 weeks
|
Example: sleep, activity |
Up to 16 weeks
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Disturbi correlati a traumi e fattori di stress
- Disordini mentali
- Disturbi da stress, traumatici
- Disturbi da stress, post-traumatici
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Alcaloidi
- Indoli
- Alcaloidi indolo
- Indolizidine
- Indolizine
- Triptamine
- Psilocibina
Altri numeri di identificazione dello studio
- 23-230
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .